Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Abstract Text:

Chien-Wen Tseng,Carol M Mangione,Robert H Brook,Emmett Keeler,R Adams Dudley,

CONTEXT: Clinicians can find it difficult to know which drugs are covered for their Medicare patients because formularies vary widely among Medicare Part D plans and many states have 50 or more such plans. OBJECTIVE: To determine whether Part D formularies in California (the state with the most Medicare beneficiaries) and Hawaii have at least 1 drug within each of 8 treatment classes for hypertension, hyperlipidemia, and depression that can be identified for clinicians as "widely covered" by the vast majority of Part D plans. DESIGN AND SETTING: Use of the medicare.gov Web site (March 1-April 15, 2006) to examine 72 California and 43 Hawaii Part D formularies' coverage of 8 treatment classes (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs were widely covered (defined as inclusion in >or=90% of formularies at co-payments of

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Publishing Authors By Initials

CW Tseng,CM Mangione,RH Brook,E Keeler,RA Dudley,

For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

PUBMED ID PMID:

MEDLINE DATE:

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: JAMA : the journal of the American Medical Associa

VOLUME: 297

Page Numbers: 2596-602

Journal Abbreviation: JAMA

ISSN: 1538-3598

DAY: 20

MONTH: Jun

YEAR: 2007

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7501160

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Keywords Mesh Terms:

KEYWORDS: United States

MESH TERMS: economics

Chemical & Substance for Abstract: Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. Information

Substance Name: Drugs, Generic

Registry Number: 0

Grant and Affiliation Information for Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.

AFFILIATION: Department of Family Medicine and Community Health, John A. Burns School of Medicine at University of Hawaii, Honolulu, USA. cwtseng@hawaii.edu

Country: United States

AGENCY: United States NIA

GRANT: AG21684

ACRONYM: AG

MEDLINETA: JAMA

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identifying widely covered drugs and drug coverage variation among Medicare part D formularies Related Publications

• 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation.
• A Boisen reverie.
• A sodium channel pore mutation causing Brugada syndrome.
• A tandem carbanion addition/carbon-carbon bond cleavage yields alkynyl ketones.
• A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling.
• ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.
• Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation.
• Characterization of green fluorescent protein-expressing retinal cells in CD 44-transgenic mice.
• Determination of gallium in biological materials.
• Diabetic-associated stillbirth: incidence, pathophysiology, and prevention.
• Early determinants of H2O2-induced endothelial dysfunction.
• Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.
• Generation and characterization of 0.6-THz polarization domain-wall trains in an ultralow-birefringence spun fiber.
• Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel.
• Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
• Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation.
• Muscle pain prophylaxis.
• Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias.
• Optimization of apodization functions in terahertz transient spectrometry.
• Oxidative stress markers are associated with persistent atrial fibrillation.
• Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model.
• Physiological Responses of Combining Electrical Stimulation of the Thighs with Voluntary Arm Exercise on the NuStep(R): 2549: Board #96 June 2 9:30 AM - 11:00 AM.
• Post stroke fatigue--where is the evidence to guide practice?
• Prediction of Atrial Fibrillation following Cardiac Surgery using Rough Set Derived Rules.
• Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury.
• Skin bacteria and Op Site((R)) chest dressings.
• Sustaining evidence-based practice for young people who self-harm: a 4-year follow-up.
• Synthesis of benzyl esters using 2-benzyloxy-1-methylpyridinium triflate.
• Use of trifluoroacetic acid to quantify small, polar compounds in rat plasma during discovery-phase pharmacokinetic evaluation.
• Variable-frequency-train stimulation of skeletal muscle after spinal cord injury.